On June 20, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced that it has reached a settlement with Perrigo Pharmaceutical Co. and Catalent Pharma Solutions LLC with respect to four patents for Teva’s ProAir® HFA (albuterol sulfate) Inhalation Aerosol product. This settlement provides a license to Perrigo and Catalent to sell limited units of Perrigo’s generic version of the product for an initial period beginning Dec. 19, 2016 and lasting until June 2018, when the limits will no longer apply. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is -0.66%. On last trading day company shares ended up $52.83. Analysts mean target price for the company is $57.09. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 4.05%.
AbbVie Inc (NYSE:ABBV), in its pursuit of drugmaker Shire Plc (SHP), has hired some of the same advisers that Pfizer Inc. worked with in its failed push for AstraZeneca Plc. (AZN) They’re trying to learn from the experience. AbbVie Inc (NYSE:ABBV) shares advanced 0.50% in last trading session and ended the day on $56.79. ABBV Gross Margin is 76.30% and its return on assets is 14.50%. AbbVie Inc (NYSE:ABBV) quarterly performance is 10.92%.
On June 25, Biogen Idec Inc (NASDAQ:BIIB) Canada announced that TECFIDERA is now available for reimbursement in British Columbia through B.C. PharmaCare. Effective June 24, TECFIDERA is now eligible for reimbursement as a first-line monotherapy for people diagnosed with RRMS according to the current McDonald clinical criteria and magnetic resonance imaging evidence, when prescribed by a neurologist from a designated MS clinic, who meet the following criteria: is 18 years of age or older; meet the Limited Coverage criteria; has had at least two disabling attacks of MS in the previous two years; and is ambulatory with or without aid with an Expanded Disability Status Scale score of 6.5 or less. Biogen Idec Inc (NASDAQ:BIIB) shares moved down -0.16% in last trading session and was closed at $318.13, while trading in range of $315.67 – $320.99. Biogen Idec Inc (NASDAQ:BIIB) year to date (YTD) performance is 13.79%.
On June 16, 2014, Amgen, Inc. (NASDAQ:AMGN) announced that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a groundbreaking new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol. Amgen, Inc. (NASDAQ:AMGN) ended the last trading day at $118.59. Company weekly volatility is calculated as 1.95% and price to cash ratio as 4.53. Amgen, Inc. (NASDAQ:AMGN) showed a positive weekly performance of 0.63%.
On June 26, AstraZeneca plc (ADR) (NYSE:AZN) announced that the FDA’s Oncologic Drugs Advisory Committee (:ODAC) voted against (11-2) accelerated approval of its oncology candidate, olaparib. The company is looking to get olaparib approved as a maintenance treatment for patients suffering from platinum-sensitive relapsed ovarian cancer with the germline BRCA mutation, and who are in complete or partial response to platinum-based chemotherapy. AstraZeneca plc (ADR) (NYSE:AZN) shares moved down -0.04% in last trading session and was closed at $74.10, while trading in range of $74.07 – $74.52. AstraZeneca plc (ADR) (NYSE:AZN) year to date (YTD) performance is 28.40%.